November 16, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) broke ground on a $200 million manufacturing facility in the city of Zaragoza, Spain.
The new site, will initially encompass 8,000 square meters (86,000 square feet) and expected to open in late 2023.
BD’s Zaragoza team will produce drug delivery devices, primarily for biopharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs. The new plant will add needed capacity to support major vaccination campaigns going forward, such as the one currently taking place for the COVID-19 pandemic.
BD will also be hiring operators and production staff to oversee the production lines closer to the site’s opening date in 2023. The site will meet high sustainability and eco-efficiency standards. By 2030, the site is expected to employ up to 600 people with an area of 30,000 square meters (323,000 square feet).
The new site is part of the $1.2 billion, four-year USD investment that was announced in late 2020 to expand and upgrade BD’s manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems as part of the company’s 2025 growth strategy.
The Zaragoza facility will mark BD’s fourth facility in Spain, where it currently has three production plants employing approximately 1,500 employees: San Agustín de Guadalix, Fraga and Almaraz.